ENDPOINTS

Plus, news about IN8bio, Sanofi, Vi­core Phar­ma, Carther­ics, Zephyrm Bio­science, Tharim­mune and In­tract Phar­ma: Bio­haven’s $250M of­fer­ing: The move comes af­ter Bio­haven an­nounced Mon­day that

Plus, news about BioAge, Ful­crum Ther­a­peu­tics and Ar­cutis Bio­ther­a­peu­tics: Sanofi snags Greater Chi­na rights to CD73 an­ti­body: The French phar­ma Sign up to read this

Plus, news about Adap­ti­m­mune, Roche, LIfT Bio­Sciences, Ver­Im­mune, and Re­vance Ther­a­peu­tics: Capri­cor Ther­a­peu­tics to file Duchenne car­diomy­opa­thy treat­ment with the FDA: The San Diego-based biotech

Plus, news about Longevi­ty Bio­med­ical, Sen­so­ri­on, Te­va and Bris­tol My­ers Squibb: Con­text Ther­a­peu­tics buys a T cell en­gager: The biotech will Sign up to read

Plus, news about GSK, No­vo Nordisk, Tanai Ther­a­peu­tics, Nom­ic Bio, Brenus Phar­ma, Xspray, Achilles Ther­a­peu­tics, BioX­cel Ther­a­peu­tics and Nu­va­lent: As­cendis’ $300M of­fer­ing: The Dan­ish com­pa­ny

Plus, news about Vig­il Neu­ro­science, AC Im­mune and Athi­ra Phar­ma: Capri­cor Ther­a­peu­tics, Nip­pon Shinyaku ex­pand com­mer­cial pact in­to Eu­rope: The Sign up to read this

Plus, news about As­cendis Phar­ma, Ko­r­ro Bio, No­vo Nordisk and Medexus: Nu­va­lent of­fers $350M in shares: The on­col­o­gy biotech is look­ing to Sign up to

Plus, news about Oru­ka Ther­a­peu­tics, Centes­sa, Take­da, In­nate Phar­ma and Liq­uidia: GSK’s mR­NA flu vac­cine suc­ceeds against both strains in Phase 2: The phar­ma com­pa­ny

Plus, news about Xen­cor, Bam­busa Ther­a­peu­tics, Grin Ther­a­peu­tics and Vax­cyte: Im­muno­vant re­ports Phase 2a Graves’ dis­ease da­ta: Pa­tients tak­ing ba­to­climab for 12 weeks saw a

Plus, news about the Glad­stone In­sti­tutes, Im­mu­ni­ty­Bio, Keen Vi­sion Ac­qui­si­tion Cor­po­ra­tion and Med­era: Basilea Phar­ma­ceu­ti­ca earns $25M mile­stone from Pfiz­er: The pay­ment Sign up to